ReviewCureus2026
Precision Medicine in Treating Lung Cancer: A Narrative Review on Treatments Targeting Oncogenic Genetic Mutations.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is among the leading causes of cancer-related mortality worldwide. It is classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being more prevalent. There have been advancements in managing extensive research on immunotherapy agents, oncolytic viruses, and targeted therapies by understanding the genetic mutations and molecular mechanisms behind lung cancer. Targeted therapy is the new paradigm in the treatment of lung cancer, especially NSCLC, and the aim is to inhibit specific proteins involved in cancer growth and progression. They primarily utilize small molecule inhibitors, monoclonal antibodies (mAbs), and antibody-drug conjugates (ADCs) to attack specific oncogenic driver mutations such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma viral oncogene homolog (KRAS), c-ros oncogene 1 (ROS1), and immune checkpoint pathways. These agents have improved outcomes and have shown efficacy in clinical trials, making them a preferred option over traditional chemotherapy. However, the associated adverse effects of these agents, along with drug resistance, remain a challenge. In this review, we discuss targeted therapies for lung cancer, their efficacy, clinical trials, adverse effects, mechanisms of resistance, and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.